Anti-inflammatory and anticatabolic effects of short-term beta-hydroxy-beta-methylbutyrate supplementation on chronic obstructive pulmonary disease patients in intensive care unit.
Elevated inflammatory markers and muscle wasting were common in chronic obstructive pulmonary disease (COPD) patients. The purpose of this study was to investigate the effect of 7-day beta-hydroxy-beta-methylbutyrate (HMB) supplementation on inflammation, protein metabolism, and pulmonary function in COPD patients in an intensive care unit. Thirty-four COPD patients who required mechanical ventilators were randomly assigned to HMB (n=18) or control (n=16) groups. The HMB group received HMB 3 g/d for 7 days. White blood cell count, C-reactive protein, and creatinine were significantly lower, while cholesterol and total protein were significantly higher after HMB supplementation. The body weight remained unchanged in both groups. Ten subjects (55.6%) in the HMB group and 4 subjects (25.0%) in the control group had improved pulmonary function, indicated by their ventilator modes. This short-term study suggests that HMB supplementation may have anti-inflammatory and anticatabolic effect and improve pulmonary function in COPD patients in an intensive care unit setting.
Hsieh
Lan-Chi
LC
Department of Dietetics, Kaohsiung Municipal United Hospital, Kaohsiung, Taiwan, ROC.
Chien
Shu-Ling
SL
Huang
Ming-Shong
MS
Tseng
Hung-Fu
HF
Chang
Chen-Kang
CK
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D019587:Dietary Supplements; D004734:Energy Metabolism / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D007958:Leukocyte Count; D008168:Lung / Q000187:drug effects* / Q000502:physiology; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012129:Respiratory Function Tests; D016896:Treatment Outcome; D014631:Valerates / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D014631:Valerates; C004961:beta-hydroxyisovaleric acid; D002097:C-Reactive Protein; D002784:Cholesterol; D003404:Creatinine